NCT02092740

Brief Summary

Retrospective analysis of treatment outcome and side effects of testicular cancer patients that had been diagnosed at the University Magdeburg from 1960 until 2012.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2012

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2012

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

March 14, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 20, 2014

Completed
Last Updated

March 24, 2014

Status Verified

March 1, 2014

Enrollment Period

1 month

First QC Date

March 14, 2014

Last Update Submit

March 20, 2014

Conditions

Testicular Cancer

Keywords

Testicular cancer

Outcome Measures

Primary Outcomes (1)

  • Overall survival (OS)

    Overall survival (OS).

    Up to 52 years.

Secondary Outcomes (9)

  • Disease-specific survival.

    Up to 52 years.

  • Chronic side effects of testicular-cancer-specific radiation therapies.

    Up to 52 years.

  • Chronic side effects of testicular-cancer-specific chemotherapies.

    Up to 52 years.

  • Chronic side effects of testicular-cancer-specific surgical therapies.

    Up to 52 years.

  • Secondary Malignoma

    Up to 52 years.

  • +4 more secondary outcomes

Study Arms (2)

Seminoma

Seminoma

Non-Seminoma

Non-Seminoma

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Testicular cancer histopathologically diagnosed at the University Magdeburg 1960-2012

You may qualify if:

  • testicular cancer histopathologically diagnosed at the University Magdeburg Germany

You may not qualify if:

  • none.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Urology University Magdeburg

Magdeburg, Saxony-Anhalt, 39120, Germany

Location

MeSH Terms

Conditions

Testicular Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesEndocrine System DiseasesTesticular DiseasesGonadal Disorders

Study Officials

  • Johann J Wendler, Dr. Med.

    Department of Urology University Magdeburg Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. med. Johann Jakob Wendler

Study Record Dates

First Submitted

March 14, 2014

First Posted

March 20, 2014

Study Start

November 1, 2012

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

March 24, 2014

Record last verified: 2014-03

Locations

DE(1)